Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 1 4Phase 2 3Phase 3 1Phase 2/3 1

Status

Terminated 1Suspended 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 6INDUSTRY 4NETWORK 3NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 4Endocrine 4Thoracic 3Dermatologic 2Other hematologic neoplasm 1Myeloid 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Neoplasms 1522Carcinoma, Non-Small-Cell Lung 758Breast Neoplasms 572Neoplasm Metastasis 531Colorectal Neoplasms 448Melanoma 390Leukemia, Myeloid, Acute 371Multiple Myeloma 364Ovarian Neoplasms 354Recurrence 336Lymphoma 334Advanced Solid Tumors 326Lymphoma, Non-Hodgkin 315Prostatic Neoplasms 302Pancreatic Neoplasms 285Advanced Solid Tumor 240Stomach Neoplasms 234Carcinoma, Renal Cell 226Squamous Cell Carcinoma of Head and Neck 211Lung Neoplasms 211Solid Tumor 204Leukemia, Lymphocytic, Chronic, B-Cell 198Triple Negative Breast Neoplasms 185Solid Tumors 183Carcinoma, Hepatocellular 165Hematologic Neoplasms 155Head and Neck Neoplasms 153Lymphoma, Large B-Cell, Diffuse 148Lymphoma, Follicular 146Glioblastoma 145

Interventions

dabrafenib 1PLX8394 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Thyroid Carcinoma, Anaplastic × Clear all
NCT07181720 2025-10-02

CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors

Chongqing Precision Biotech Co., Ltd

Phase 1 Recruiting
90 enrolled
EndocrineGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Thymoma, Thyroid Carcinoma, Anaplastic

NCT04418167 2025-09-03

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

JS InnoPharm, LLC

Phase 1 Suspended
71 enrolled
DermatologicEndocrineHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Thyroid Carcinoma, Anaplastic

NCT04420754 2025-03-30

Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer

AffyImmune Therapeutics, Inc.

Phase 1 Active not recruiting
70 enrolled
EndocrineHead & Neck

Recurrence, Thyroid Carcinoma, Anaplastic

NCT02012231 2020-10-19

Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.

Fore Biotherapeutics

Phase 1 Terminated
5 enrolled
DermatologicEndocrineGastrointestinalHead & NeckMyeloidOther hematologic neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Leukemia, Hairy Cell, Melanoma, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis, Cholangiocarcinoma, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡